Dvrt-006

| Feature | DVRT-006 | AAV (Current Standard) | CRISPR-Cas9 | | :--- | :--- | :--- | :--- | | | Low (Safe harbor docking) | Moderate (Random integration) | High (Off-target double-strand breaks) | | Cargo Capacity | Very High (20+ kb) | Low (<5 kb) | Variable (editors only) | | Immunogenicity | Very Low (Synthetic) | High (Pre-existing antibodies) | Moderate | | Re-dosing | Yes | No (Neutralizing antibodies form) | Limited | | Cell Type | Non-dividing & dividing | Primarily dividing | Actively dividing |

Disclaimer: This article is for informational purposes based on current pre-clinical data and scientific publications. DVRT-006 is an investigational product and is not approved for human use by the FDA, EMA, or any global regulatory body. DVRT-006

For patients suffering from giant-gene disorders like DMD or CF, DVRT-006 offers hope where AAVs fall short. For the biotech industry, it offers a platform that combines re-dosability, safety, and massive cargo space. However, the path from pre-clinical promise to bedside reality is fraught with manufacturing and regulatory landmines. | Feature | DVRT-006 | AAV (Current Standard)